Reaction is mixed to the proposal by the Centers for Medicare and Medicaid Services to limit Medicare beneficiaries’ access to monoclonal antibody treatments that target amyloid for the treatment of Alzheimer’s, to those enrolled in qualifying clinical trials.
Stakeholders have mixed reaction to CMS proposal to limit use of Alzheimer drug, Aduhelm
